NS Biomedical Technology Aims To Improve Wound Healing
November 15th, 2013
Halifax-based DeCell Technologies Inc. has come up with a better way to produce skin grafts for wound treatment. With a $250,000 equity investment from Innovacorp, the company will complete the development and human testing of its first product for the treatment of diabetic foot ulcers. DeCell was co-founded in 2012 by Mr. Gratzer, a biomedical engineer at Dalhousie University, and vice-president Sean Margueratt, an engineer with extensive experience in tissue banking.
A Dalhousie technology, this work has been funded by the Canadian Institutes of Health Research (CIHR), Innovacorp, Springboard Atlantic, Halifax Capital District Health Authority (CDHA), and the Atlantic Canada Opportunities Agency (ACOA).